BioMarin Pharmaceutical Inc.
BMRN
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPSā¦ read more
Healthcare
Biotechnology
26 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$51.46
Price-0.73%
-$0.38
1Y
Price
Market Cap
$9.886b
Mid
Price/Earnings 3y Avg5y Avg
19.1x
Premium
Premium
Financials Overview
Key metrics over the past few years-0.7%
EBITDA Margin-4.0%
Net Profit Margin+43.8%
Free Cash Flow MarginRevenue
$3.094b
+8.4%
1y CAGR+13.9%
3y CAGR+13.8%
5y CAGREarnings
$520.417m
+21.9%
1y CAGR+65.0%
3y CAGR+129.0%
5y CAGREPS
$2.66
+20.4%
1y CAGR+62.9%
3y CAGR+125.8%
5y CAGRBook Value
$6.057b
$7.615b
Assets$1.558b
Liabilities$596.663m
DebtDebt to Assets
7.8%
0.8x
Debt to EBITDAFree Cash Flow
$831.362m
+74.9%
1y CAGR+303.9%
3y CAGR+208.9%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company